… Disclosure: Dr Gooderham has served as an investigator, speaker, consultant and
advisory board member for AbbVie, Actelion, Akros, Amgen, Boehringer Ingelheim, Bristol-Myers …

Introduction: Generalized pustular psoriasis (GPP) is a rare, severe relapsing/remitting,
multisystem disease that can be difficult to treat. Recent clinical, histological, and genetic …

Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis
have advanced considerably in recent years, and in parallel, so too have the available …

… Dr Gooderham reports being an investigator, speaker, advisor, or consultant for AbbVie,
Akros, Amgen, Arcutis, BMS, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, …

… Author Contributions: Dr Gooderham had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis. …

… Dr Gooderham reported receiving investigator fees, speaker fees, and/or honoraria from
AbbVie, Akros, Amgen, Arcutis Biotherapeutics Inc, Aslan, Bristol Myers Squibb, Boehringer …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent for …

Atopic dermatitis is one of the most common skin disorders in the developed world, affecting
up to 20% of children and 1% to 3% of adults. This review concisely explains the …

Background Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective
in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being …

… Dr Melinda J Gooderham has been an investigator, speaker, consultant or advisory board
member for AbbVie, Amgen, Akros, Arcutis, Boehringer Ingelheim, BMS, Celgene, Dermira, …